MERCK KGAA |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 145.4 EUR | -0.92% |
|
-5.57% | +0.66% |
| 10:09am | MERCK KGAA : Barclays reiterates its Buy rating | ZD |
| Apr. 18 | Study: US companies outpace Europe and Asia in research spending | DP |
Presenter SpeechConstantin Fest (Executives)Dear ladies and gentlemen, a very warm welcome to ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows:
- solutions and products for scientific and biotechnological research (44.2%);
- pharmaceutical products (38.4%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.;
- performance materials for the electronics industry (17.4%): semiconductor materials, liquid crystals, pigments and additives, carbon-based organic materials, etc.
Net sales are distributed geographically as follows: Germany (4.8%), Europe (24%), China (12.9%), Asia/Pacific (20.1%), the United States (26.8%), North America (1.6%), Latin America (6.3%), Middle East and Africa (3.5%).
Sector
Pharmaceuticals
Calendar
2024-04-25
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
146.8
EUR
Average target price
182
EUR
Spread / Average Target
+24.02%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.66% | 68.04B | |
| +10.08% | 9.12B | |
| -15.94% | 4.8B | |
| +18.47% | 3.72B | |
| +1.89% | 3.8B | |
| +26.34% | 2.58B | |
| -24.63% | 2.36B | |
| -29.37% | 2.11B | |
| +2.55% | 1.86B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- MRK Stock
- News Merck KGaA
- Transcript : MERCK Kommanditgesellschaft auf Aktien - Analyst/Investor Day
